Cognitive effects of second-generation antipsychotics: Current insights into neurochemical mechanisms

CNS Drugs

Volumn 23, Issue 7, 2009, Pages 603-614

  Fumagalli, Fabio ^a   Frasca, Angelisa ^a   Racagni, Giorgio ^a,b   Riva, Marco Andrea ^a  

^a Center of Neuropharmacology   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; DIZOCILPINE; DOPAMINE; GLUTAMIC ACID; HALOPERIDOL; METHAMPHETAMINE; NEUROLEPTIC AGENT; NEUROTROPHIC FACTOR; OLANZAPINE; PHENCYCLIDINE; QUETIAPINE; QUINPIROLE; SEROTONIN; ZIPRASIDONE;

COGNITIVE DEFECT; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; EXTRAPYRAMIDAL SYMPTOM; HIPPOCAMPUS; HUMAN; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC NERVE; PATHOGENESIS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPSE;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HUMANS; NEURONAL PLASTICITY; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 67649406118     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/00023210-200923070-00005     Document Type: Review

References (136)

1. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophr Bull 2000; 26 (1): 119-36
2. Bressan RA, Costa DC, Jones HM, et al. Typical antipsychotic drugs: D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002 Jul 1; 56 (1-2): 31-6
3. de Haan L, van Bruggen M, Lavalaye J, et al. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003 Feb; 160 (2): 303-9
4. Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 2006 Jul; 85 (1-3): 222-31
5. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008 Apr; 28 (2): 203-9
6. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors: implications for atypical antipsychotic action. J Psychiatry Neurosci 2000 Mar; 25 (2): 161-6
7. Riedel M, Muller N, Spellmann I, et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2007 Oct; 257 (7): 402-12
8. Abdul-Monim Z, Reynolds GP, Neill JC. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 2006 May 15; 169 (2): 263-73
9. He J, Yang Y, Yu Y, et al. The effects of chronic administration of quetiapine on the methamphetamine-induced recognition memory impairment and dopaminergic terminal deficit in rats. Behav Brain Res 2006 Sep 15; 172 (1): 39-45
10. Bardgett ME, Griffith MS, Foltz RF, et al. The effects of clozapine on delayed spatial alternation deficits in rats with hippocampal damage. Neurobiol Learn Mem 2006 Jan; 85 (1): 86-94
11. Addy NA, Pocivavsek A, Levin ED. Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions. Neuropsychopharmacology 2005 Jun; 30 (6): 1121-7
12. Terry Jr AV, Mahadik SP. Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. J Pharmacol Exp Ther 2007 Mar; 320 (3): 961-8
13. Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006 Sep; 67 (9): e11
14. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007 Feb; 90 (1-3): 86-96
15. Devoto P, Flore G, Vacca G, et al. Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. Psychopharmacology (Berl) 2003 Apr; 167 (1): 79-84
16. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 1990 May; 54 (5): 1755-60
17. Diaz-Mataix L, Scorza MC, Bortolozzi A, et al. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 2005 Nov 23; 25 (47): 10831-43
18. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999 Feb; 288 (2): 774-81
19. Yamamoto BK, Cooperman MA. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 1994 Jul; 14 (7): 4159-66
20. Lidow MS, Goldman-Rakic PS, Gallager DW, et al. Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience 1991; 40 (3): 657-71
21. Hurd YL, Suzuki M, Sedvall GC. D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. J Chem Neuroanat 2001 Jul; 22 (1-2): 127-37
22. Brozoski TJ, Brown RM, Rosvold HE, et al. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979 Aug 31; 205 (4409): 929-32
23. Arnsten AF, Cai JX, Murphy BL, et al. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 1994 Oct; 116 (2): 143-51
24. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995 Aug 17; 376 (6541): 572-5
25. Granon S, Passetti F, Thomas KL, et al. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 2000 Feb 1; 20 (3): 1208-15
26. Castner SA, Williams GV. Tuning the engine of cognition: a focus on NMDA/D1 receptor interactions in prefrontal cortex. Brain Cogn 2007 Mar; 63 (2): 94-122
27. Shoemaker JM, Saint Marie RL, Bongiovanni MJ, et al. Prefrontal D1 and ventral hippocampal N-methyl-D-aspartate regulation of startle gating in rats. Neuroscience 2005; 135 (2): 385-94
28. Yang CR, Chen L. Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment. Neuroscientist 2005; 11: 452-70
29. Missale C, Fiorentini C, Busi C, et al. The NMDA/D1 receptor complex as a new target in drug development. Curr Top Med Chem 2006; 6 (8): 801-8
30. Wang X, Zhong P, Gu Z, et al. Regulation of NMDA receptors by dopamine D4 signaling in prefrontal cortex. J Neurosci 2003 Oct 29; 23 (30): 9852-61
31. Jentsch JD, Taylor JR, Redmond Jr DE, et al. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology (Berl) 1999 Feb; 142 (1): 78-84
32. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25 (3): 390-2
33. Stockmeier CA, DiCarlo JJ, Zhang Y, et al. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 1993 Sep; 266 (3): 1374-84
34. Rollema H, Lu Y, Schmidt AW, et al. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000 Aug 1; 48 (3): 229-37
35. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 2000 Dec; 295 (3): 853-61
36. Ichikawa J, Ishii H, Bonaccorso S, et al. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001 Mar; 76 (5): 1521-31
37. Rollema H, Lu Y, Schmidt AW, et al. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 1997 Nov 5; 338 (2): R3-5
38. Newman-Tancredi A, Gavaudan S, Conte C, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 1998 Aug 21; 355 (2-3): 245-56
39. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25 (2): 233-55
40. Gallhofer B, Lis S, Meyer-Lindenberg A, et al. Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects. Acta Psychiatr Scand Suppl 1999; 395: 118-28
41. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999 Jan 1; 45 (1): 1-16
42. Tyson PJ, Laws KR, Flowers KA, et al. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. Psychiatry Clin Neurosci 2006 Aug; 60 (4): 473-9
43. Tyson PJ, Roberts KH, Mortimer AM. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci 2004 Jun; 114 (6): 593-611
44. Sumiyoshi T, Bubenikova-Valesova V, Horacek J, et al. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv Ther 2008; 25: 1037-56
45. Hirst WD, Stean TO, Rogers DC, et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 2006 Dec 28; 553 (1-3): 109-19
46. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 2004 Jun; 174 (1): 17-24
47. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400-11
48. Arnsten AF. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl) 2004 Jun; 174 (1): 25-31
49. Franowicz JS, Kessler LE, Borja CM, et al. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci 2002 Oct 1; 22 (19): 8771-7
50. Devoto P, Flore G, Longu G, et al. Origin of extracellular dopamine from dopamine and noradrenaline neurons in the medial prefrontal and occipital cortex. Synapse 2003 Dec 1; 50 (3): 200-5
51. Fields RB, Van Kammen DP, Peters JL, et al. Clonidine improves memory function in schizophrenia independently from change in psychosis: preliminary findings. Schizophr Res 1988; 1: 417-23
52. Friedman JI, Adler DN, Temporini HD, et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 2001; 25: 402-9
53. Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 2007 Mar; 113 (3): 523-36
54. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991 Nov; 148 (11): 1474-86
55. Crook JM, Tomaskovic-Crook E, Copolov DL, et al. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 2000 Sep 1; 48 (5): 381-8
56. Hasselmo ME, Bower JM. Acetylcholine and memory. Trends Neurosci 1993 Jun; 16 (6): 218-22
57. Raedler TJ, Bymaster FP, Tandon R, et al. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007 Mar; 12 (3): 232-46
58. Breese CR, Lee MJ, Adams CE, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000 Oct; 23 (4): 351-64
59. Freedman R, Adams CE, Leonard S. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat 2000 Dec; 20 (3-4): 299-306
60. Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004 Jan; 161 (1): 116-24
61. Ferreri F, Agbokou C, Gauthier S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci 2006; 31: 369-76
62. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 2002 Mar 1; 51 (5): 349-57
63. Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 2002 May; 26 (5): 583-94
64. Ichikawa J, Chung YC, Li Z, et al. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 2002 Dec 20; 958 (1): 176-84
65. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996 Feb; 14 (2): 87-96
66. Koyama T, Nakajima Y, Fujii T, et al. Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by BAY x 3702 in freely moving rats. Neurosci Lett 1999 Apr 9; 265 (1): 33-6
67. Kurokawa M, Shiozaki S, Nonaka H, et al. In vivo regulation of acetylcholine release via adenosine A1 receptor in rat cerebral cortex. Neurosci Lett 1996 May 17; 209 (3): 181-4
68. Tellez S, Colpaert F, Marien M. Acetylcholine release in the rat prefrontal cortex in vivo: modulation by alpha 2-adrenoceptor agonists and antagonists. J Neurochem 1997 Feb; 68 (2): 778-85
69. McDonald MP, Willard LB, Wenk GL, et al. Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions. J Neurosci 1998 Jul 1; 18 (13): 5078-85
70. Hodges H, Peters S, Gray JA, et al. Counteractive effects of a partial (sabcomeline) and a full (RS86) muscarinic receptor agonist on deficits in radial maze performance induced by S-AMPA lesions of the basal forebrain and medial septal area. Behav Brain Res 1999 Feb 15; 99 (1): 81-92
71. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989 Nov; 98 (4): 367-80
72. Bymaster FP, Heath I, Hendrix JC, et al. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 1993 Oct; 267 (1): 16-24
73. Adams CE, Stevens KE. Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. Front Biosci 2007; 12: 4755-72
74. Bitner RS, Bunnelle WH, Anderson DJ, et al. Broadspectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 2007; 27: 10578-87
75. Buchanan RW, Freedman R, Javitt DC, et al. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007 Sep; 33 (5): 1120-30
76. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991 Oct; 148 (10): 1301-8
77. Fitzgerald LW, Deutch AY, Gasic G, et al. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 1995 Mar; 15 (3 Pt 2): 2453-61
78. Heresco-Levy U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003 Oct; 27 (7): 1113-23
79. Corbett R, Camacho F, Woods AT, et al. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 1995 Jul; 120 (1): 67-74
80. Gaisler-Salomon I, Weiner I. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology (Berl) 2003 Apr; 166 (4): 333-42
81. Abekawa T, Ito K, Koyama T. Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic. Naunyn Schmiedebergs Arch Pharmacol 2007 Jun; 375 (4): 261-71
82. Daly DA, Moghaddam B. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 1993 Apr 2; 152 (1-2): 61-4
83. Ninan I, Wang RY. Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: pharmacological evidence. Eur J Neurosci 2003 Mar; 17 (6): 1306-12
84. Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008; 60: 358-403
85. Kyosseva SV. Differential expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004 Sep; 28 (6): 997-1006
86. Kyosseva SV. The role of the extracellular signal-regulated kinase pathway in cerebellar abnormalities in schizophrenia. Cerebellum 2004; 3 (2): 94-9
87. Emamian ES, Hall D, Birnbaum MJ, et al. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004 Feb; 36 (2): 131-7
88. Beasley C, Cotter D, Khan N, et al. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett 2001 Apr 20; 302 (2-3): 117-20
89. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 2000 May; 157 (5): 831-3
90. Cotter D, Kerwin R, Al-Sarraji S, et al. Abnormalities of Wnt signalling in schizophrenia: evidence for neurodevelopmental abnormality. Neuroreport 1998 May 11; 9 (7): 1379-83
91. Alimohamad H, Rajakumar N, Seah YH, et al. Antipsychotics alter the protein expression levels of betacatenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005 Mar 1; 57 (5): 533-42
92. Alimohamad H, Sutton L, Mouyal J, et al. The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats. J Neurochem 2005 Oct; 95 (2): 513-25
93. Fumagalli F, Frasca A, Sparta M, et al. Long-term exposure to the atypical antipsychotic olanzapine differently up-regulates extracellular signal-regulated kinases 1 and 2 phosphorylation in subcellular compartments of rat prefrontal cortex. Mol Pharmacol 2006 Apr; 69 (4): 1366-72
94. Ahmed MR, Gurevich VV, Dalby KN, et al. Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. J Pharmacol Exp Ther 2008 Apr; 325 (1): 276-83
95. Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 2004 Jun; 14 (3): 311-17
96. Dwivedi Y, Rizavi HS, Pandey GN. Differential effects of haloperidol and clozapine on [(3)H]cAMP binding, protein kinase A (PKA) activity, and mRNA and protein expression of selective regulatory and catalytic subunit isoforms of PKA in rat brain. J Pharmacol Exp Ther 2002 Apr; 301 (1): 197-209
97. Ramos BP, Birnbaum SG, Lindenmayer I, et al. Dysregulation of protein kinase A signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. Neuron 2003 Nov 13; 40 (4): 835-45
98. Barad M, Bourtchouladze R, Winder DG, et al. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci U S A 1998 Dec 8; 95 (25): 15020-5
99. Beaulieu JM. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int J Neuropsychopharmacol 2007 Feb; 10 (1): 3-6
100. Lipska BK, Khaing ZZ, Weickert CS, et al. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci 2001 Jul; 14 (1): 135-44
101. Molteni R, Lipska BK, Weinberger DR, et al. Developmental and stress-related changes of neurotrophic factor gene expression in an animal model of schizophrenia. Mol Psychiatry 2001 May; 6 (3): 285-92
102. Fumagalli F, Bedogni F, Perez J, et al. Corticostriatal brain-derived neurotrophic factor dysregulation in adult rats following prenatal stress. Eur J Neurosci 2004 Sep; 20 (5): 1348-54
103. Fiore M, Korf J, Antonelli A, et al. Long-lasting effects of prenatal MAM treatment on water maze performance in rats: associations with altered brain development and neurotrophin levels. Neurotoxicol Teratol 2002 Mar-Apr; 24 (2): 179-91
104. Angelucci F, Mathe AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000 Jun 15; 60 (6): 783-94
105. Chlan-Fourney J, Ashe P, Nylen K, et al. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res 2002 Nov 1; 954 (1): 11-20
106. Bai O, Chlan-Fourney J, Bowen R, et al. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003 Jan 1; 71 (1): 127-31
107. Parikh V, Khan MM, Mahadik SP. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett 2004 Feb 12; 356 (2): 135-9
108. Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res 2005 Nov 23; 1063 (1): 32-9
109. Xu H, Qing H, Lu W, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 2002 Mar 15; 321 (1-2): 65-8
110. Thacker SK, Perna MK, Ward JJ, et al. The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. Eur J Neurosci 2006 Oct; 24 (7): 2075-83
111. Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 2005 May; 15 (3): 319-29
112. Christie BR, Cameron HA. Neurogenesis in the adult hippocampus. Hippocampus 2006; 16 (3): 199-207
113. Abrous DN, Koehl M, Le Moal M. Adult neurogenesis: from precursors to network and physiology. Physiol Rev 2005 Apr; 85 (2): 523-69
114. Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci 2005; 28: 223-50
115. Aimone JB, Wiles J, Gage FH. Potential role for adult neurogenesis in the encoding of time in new memories. Nat Neurosci 2006 Jun; 9 (6): 723-7
116. Gould E. How widespread is adult neurogenesis in mammals? Nat Rev Neurosci 2007 Jun; 8 (6): 481-8
117. Bruel-Jungerman E, Rampon C, Laroche S. Adult hippocampal neurogenesis, synaptic plasticity and memory: facts and hypotheses. Rev Neurosci 2007; 18 (2): 93-114
118. Gould E, Tanapat P, Hastings NB, et al. Neurogenesis in adulthood: a possible role in learning. Trends Cogn Sci 1999 May; 3 (5): 186-92
119. Wang HD, Dunnavant FD, Jarman T, et al. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004 Jul; 29 (7): 1230-8
120. Mirescu C, Gould E. Stress and adult neurogenesis. Hippocampus 2006; 16 (3): 233-8
121. Malberg JE, Duman RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 2003 Sep; 28 (9): 1562-71
122. Weiner I, Schiller D, Gaisler-Salomon I, et al. A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine. Behav Pharmacol 2003 May; 14 (3): 215-22
123. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008; 11 (7): 999-1029
124. Kodama M, Fujioka T, Duman RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004 Oct 15; 56 (8): 570-80
125. Halim ND, Weickert CS, McClintock BW, et al. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 2004 Jun; 29 (6): 1063-9
126. Fan Y, Liu Z, Weinstein PR, et al. Environmental enrichment enhances neurogenesis and improves functional outcome after cranial irradiation. Eur J Neurosci 2007 Jan; 25 (1): 38-46
127. Newton SS, Duman RS. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 2007; 21 (9): 715-25
128. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002 Jun; 159 (6): 1018-28
129. Purdon SE. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. J Psychiatry Neurosci 2000 Mar; 25 (2): 108-16
130. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007 Jun; 64 (6): 633-47
131. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007 Oct; 64 (10): 1115-22
132. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006 Feb; 163 (2): 185-94
133. Sweet RA, Pollock BG, Mulsant BH, et al. Pharmacologic profile of perphenazine's metabolites. J Clin Psychopharmacol 2000 Apr; 20 (2): 181-7
134. Green MF. Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu Rev Clin Psychol 2007; 3: 159-80
135. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63: 630-8
136. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165 (8): 1040-4